Jim Cramer on Hims & Hers Health, Inc. (HIMS): ‘HIMS Just Dropped It Like, It Was Like A Led Zeppelin’
We recently published an article titled Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate. In this article, we are going to take a look at where Hims & Hers Health, Inc.
Hims & Hers: A Generational Dip-Buying Opportunity
Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...
Hims & Hers Stocks Sinks Despite Huge Revenue Growth. Is This a Buying Opportunity in the Stock?
Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...
Why Hims & Hers Health Stock Sank This Week
Shares of Hims & Hers Health (NYSE: HIMS) sank 10.5% this week, according to data from S&P Global Market Intelligence. The ...
Eli Lilly takes aim at weight-loss drug copies with new ad campaign
Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...
Modern Healthcare3d
Digital health companies see opportunity in regulatory upheaval
Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...
Hims & Hers Health (NYSE:HIMS) Price Target Raised to $40.00
Hims & Hers Health (NYSE:HIMS – Free Report) had its price objective hoisted by Leerink Partners from $24.00 to $40.00 in a report published on Tuesday,Benzinga reports. They currently have a market ...
Promising Medical Stocks To Add to Your Watchlist – February 26th
Eli Lilly and Company, Hims & Hers Health, UnitedHealth Group, Walmart, Tempus AI, Johnson & Johnson, and Merck & Co., Inc. are the seven Medical stocks to watch today, according to MarketBeat’s stock ...
Modern Healthcare3d
GLP-1 compounding pharmacies sue FDA over shortage decision
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
Hims & Hers: Brace For Impact As It Faces A Possible 18% Revenue Hit
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
Why Hims & Hers Health, Inc. (HIMS) Went Down on Tuesday
We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...
Why Hims & Hers Stock Has Further to Fall: Heard on the Street
Stock in Hims & Hers Health was bound to tumble once it could no longer sell compounded versions of the weight-loss drug Wegovy at scale. But with lofty expectations about its remaining anti-obesity ...